I agree. out of the 125 companies, PPHM may not have the worst BOD. Key word here is MAY. IMO it is probably the worst. But if you think it is a corporate highlight of "possibly not the worst BOD in the biotech sector", perhaps they can update the corporate profile.
In pulling together the research I had to look at each company's board. For the most part, 7 to 9 directors with an even balance of biotech capital experience and high level biotech company management experience. That is critical IMO in the ability to steer the ship. IMO We have an incestuous group of penny stock operators that have no clue of the biotech sector nor how to get a deal done. They are way overcompensated and do nothing to earn what they get. Perhaps that is why they are so resistant to change and maybe anyone with credentials may not want to be associated with such operators. All the great science gets tossed out the window when you have a poor BOD. But drink the Kool-Aid in that the BOD is saving us from dark forces. They are the dark forces. But paying two extra BOD members would cost so much? And they diluted the company by how much? Please wake up and demand better leadership.